Drug Profile
SMRX 11
Alternative Names: Clot-buster protein; Clot-specific streptokinase; CSSK; SMRX11Latest Information Update: 22 Feb 2021
Price :
$50
*
At a glance
- Originator Institute of Microbial Technology
- Developer Nostrum Pharmaceuticals; Symmetrix Biotech
- Class Coenzymes; Plasminogen activator enzymes; Recombinant fusion proteins; Recombinant proteins; Thrombolytics
- Mechanism of Action Fibrinolytic agents; Plasmin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Myocardial infarction
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in India (IV)
- 24 Mar 2014 SMRX 11 is still in preclinical trials for thrombosis (IV) in India
- 10 Mar 2014 Symmetrix Pharmaceuticals plans a phase II trial for Myocardial infarction in India (CTRI/2014/03/004442)